The current study
evaluates antidiabetic, anticoagulant, and antiplatelet
activity of novel benzimidazole-containing quinolinyl oxadiazoles.
These derivatives are synthesized and characterized using spectroscopy
(FT-IR, 1H NMR, and mass spectroscopy) and single-crystal
X-ray diffraction methods. The inhibitory effects of these compounds
were evaluated by the α-glucosidase inhibitory assay and shows
the activity in the range of IC50 = 0.66 ± 0.05 to
3.79 ± 0.46 μg/mL. In addition, molecular docking studies
revealed that benzimidazole-containing quinolinyl oxadiazoles can
correctly dock into the target receptor protein of the human intestinal α-glucosidase, while their bioavailability/drug-likeness
was predicted to be acceptable but requires further optimization.
On the other hand, compound 8a and 8d showed
anticoagulant activity as they enhanced the clotting time from control
180–410 and 180–390 s, respectively, in platelet rich
plasma and 230–460 and 230–545 s in platelet poor plasma.
Furthermore, only 8a showed antiplatelet activity by
inhibiting epinephrine-induced platelet aggregation, and the observed
aggregation inhibition was found to be 93.4%. Compounds 8a–f show nontoxic properties because of the non-hydrolyzing properties
in the RBC cells. In addition, 8a and 8d show anti-edema and anti-hemorrhagic properties in the experimental
mice. These findings reveal that benzimidazole-containing quinolinyl
oxadiazoles act as α-glucosidase inhibitors to develop novel
therapeutics for treating type-II diabetes mellitus and can act as
lead molecules in drug discovery as potential antidiabetic and antithrombotic
agents.